MTOR

Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium

Retrieved on: 
Thursday, October 27, 2022
Time, NSCLC, Review, NASDAQ, TSC1, Mirati, Private Securities Litigation Reform Act, Cancer, EORTC, MTOR, KRAS, Forward-looking statement, AMG510, FDA, Perivascular epithelioid cell tumour, Patient, LinkedIn, Adult, Company, Partnership, AADI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, Everolimus, Food, TSC2, Mutation, Twitter, Safety, Pharmaceutical industry, Aadi

LOS ANGELES, Oct. 27, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today presented preclinical combination data of KRAS inhibitors and nab-sirolimus at the 34th EORTC-NCI-AACR Symposium. Nab-sirolimus is a novel albumin-bound nanoparticle form of the mTOR inhibitor sirolimus and is approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Key Points: 
  • The mTOR pathway is often activated in patients with the KRAS mutation and contributes to adaptive resistance to KRAS inhibitors.
  • This study investigated the preclinical antitumor activity of mTOR inhibitors nab-sirolimus or everolimus in combination with sotorasib or adagrasib in KRASG12C-mutated cancer xenografts.
  • "These preclinical results demonstrate that nab-sirolimus has the potential to significantly improve the antitumor activity of adagrasib or sotorasib, two of the most promising KRAS inhibitors today.
  • In contrast, everolimus in combination with the KRAS inhibitors was not as effective.

AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V

Retrieved on: 
Thursday, October 20, 2022
MSD, CFO, Merck, Therapy, Registration statement, IND, Merck & Co., Investigational New Drug, Securities Act of 1933, Board of directors, Mutation, CEO, Director, Failure, LLP, Nasdaq, Pedigree, MNK, Trk receptor, AUMB, Regulation of tobacco by the U.S. Food and Drug Administration, Agreement, AUM, Private Securities Litigation Reform Act, NEW, EIF4E, Industry, SPAC, GLOBE, Trichuris suis, Ownership, Leadership, MTOR, Orphan, Risk, Growth, Roche, Register, Research, Security (finance), DLA Piper, TRK, Board, U.S. Securities and Exchange Commission, Prospectus, Name, Sale, Cayman Islands, SEC, Patient, Partnership, Food, Acquisition, F-4, Form, File, Proxy, COVID-19, Health, Bank, Fine chemical, Pharmaceutical industry, Financial adviser, Risk management, Holding company, Greater China

The transaction is expected to provide approximately $69 million of cash held in Mountain Crests trust account, assuming no redemptions.

Key Points: 
  • The transaction is expected to provide approximately $69 million of cash held in Mountain Crests trust account, assuming no redemptions.
  • This merger allows AUM to further continue our focus on developing our scientifically differentiated portfolio.
  • AUM is a global clinical-stage oncology company focused on advancing a clinical stage pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance.
  • Mountain Crest and AUM caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made.

Global Rare NRG1 Fusion Market Report to 2032 - Insight, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 19, 2022
Health, Oncology, MTOR, Epidemiology, Lung, ADAM9, Pancreatic cancer, Fluorescence, SDC4, IMA, VTCN1, ERBB2, ATP1B1, Adenocarcinoma, In situ hybridization, CDH1, Ligand, Neoplasm, Rare, Patient, RNA, CSC, ErbB, SLC3A2, Cancer, Gene, Intron, Report, HER2, FISH, NGS, CD74, ZMYM2, Breast cancer, Breast, Immunotherapy, Fusion, United Kingdom, Immunohistochemistry, DNA, MAPK, Ovarian cancer, Carcinoma, Vaccine, NRG1, NSCLC

The "Rare NRG1 Fusion - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare NRG1 Fusion - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Rare NRG1 Fusion, historical and forecasted epidemiology as well as the Rare NRG1 Fusion market trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The Rare NRG1 Fusion market report provides current treatment practices, emerging drugs, Rare NRG1 Fusion market share of the individual therapies, current and forecasted Rare NRG1 Fusion market size from 2019 to 2032 segmented by seven major markets.
  • The Report also covers the current Rare NRG1 Fusion treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium

Retrieved on: 
Wednesday, October 12, 2022
MTOR, LinkedIn, Time, Risk, Review, Everolimus, TSC1, NASDAQ, Patient, Poster, 34th G8 summit, Twitter, TSC2, Cancer, KRAS, Private Securities Litigation Reform Act, LOS, Company, Mutation, NSCLC, Large-cell lung carcinoma, AADI, Adult, Safety, Forward-looking statement, AMG510, FDA, Perivascular epithelioid cell tumour, Pharmaceutical industry, Aadi

LOS ANGELES, Oct. 12, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that preclinical combination data of KRAS inhibitors and nab-sirolimus will be presented during a poster session at the upcoming 34th EORTC-NCI-AACR Symposium, taking place October 26-28, 2022 in Barcelona, Spain. Nab-sirolimus is a novel albumin-bound nanoparticle form of the mTOR inhibitor sirolimus and is approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Key Points: 
  • KRAS is frequently mutated in non-small cell lung cancer (NSCLC) and other tumor types, with the KRAS G12C present in approximately 9% of NSCLC patients.
  • The mTOR pathway is often activated in patients with the KRAS mutation and contributes to adaptive resistance to KRAS inhibitors.
  • Aadi scientists conducted studies to determine the utility of a combination of the mTOR inhibitor nab-sirolimus and KRAS inhibitors, which could have synergistic potential in the treatment of KRAS mutated cancers.
  • This study investigated the antitumor activity of mTOR inhibitors nab-sirolimus or everolimus in combination with sotorasib or adagrasib in KRAS G12C-mutated cancer xenografts.

InsightRX Offers Precision Dosing Support for New Drug Categories

Retrieved on: 
Tuesday, October 11, 2022
Quality of life, MTOR, SAN, Doctor of Pharmacy, Time, Disease, Transplant, Efficiency, Hospital, Everolimus, Machine learning, Intelligence, Patient, Research, Extrapyramidal system, Kidney, Precision medicine, Ciclosporin, Infliximab, Learning, Doctor of Philosophy, Immunodeficiency, Azole, Toxicity, Tacrolimus, IBD, Liver, Posaconazole, AUC, Adalimumab, Gastroenterology, Pharmacist, Inflammatory bowel disease, Heart, Voriconazole, Pharmaceutical industry, Generic drug, List of things named after Thomas Bayes

SAN FRANCISCO, Oct. 11, 2022 /PRNewswire/ -- Today InsightRX, a precision dosing intelligence company, announced its expansion into three new therapeutic categories with the release of point-of-care dosing guidance for antifungal drugs, solid organ transplant drugs, and inflammatory bowel disease biologics. New modules of the company's cloud-based precision dosing intelligence platform, InsightRX Nova, help clinicians rapidly achieve a therapeutic dosage and ensure continuity of care as patients transition from an inpatient setting to home, providing seamless support for outpatient therapeutic drug monitoring.

Key Points: 
  • New modules of the company's cloud-based precision dosing intelligence platform, InsightRX Nova, help clinicians rapidly achieve a therapeutic dosage and ensure continuity of care as patients transition from an inpatient setting to home, providing seamless support for outpatient therapeutic drug monitoring.
  • InsightRX Nova now offers modules for nearly every commercially available azole antifungal, including the highly sought after voriconazole and posaconazole.
  • The precision dosing platform uses patient-specific data, pharmacokinetic and pharmacodynamic models, and Bayesian forecasting to guide treatment decisions based on a patient's unique pharmacological profile.
  • InsightRX Nova's Bayesian algorithms enable clinicians to transition to AUC-based dosing, which is recommended to improve therapeutic drug monitoring of tacrolimus .

Global Graft Versus Host Disease Treatment Market 2022-2027: Rising Number of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplants Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, August 29, 2022
Health, Stem Cells, Market development, USD, Ansoff Matrix, GVHD, Preventive healthcare, Investment, Monoclonality, Geography, Graft-versus-host disease, MTOR, SWOT, CAGR, Risk, Growth, Industry, Pharmaceutical industry, Etanercept, Thalidomide

The Global Graft Versus Host Disease Treatment Market is segmented based on Disease Type, Product, and Geography.

Key Points: 
  • The Global Graft Versus Host Disease Treatment Market is segmented based on Disease Type, Product, and Geography.
  • By Disease Type, the market is classified into Acute graft vs host disease, Chronic graft vs host disease, and Prophylaxis GVHD.
  • The report presents a detailed Ansoff matrix analysis for the Global Graft Versus Host Disease Treatment Market.
  • The analyst analyses the Global Graft Versus Host Disease Treatment Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Parsemus Foundation: Metformin Drastically Reduces COVID Hospitalization, Study Shows

Retrieved on: 
Thursday, August 18, 2022
Health, Consumer, Diabetes, Infectious Diseases, Clinical Trials, Pharmaceutical, Hispanic, Parsemus Foundation, Â, The New England Journal of Medicine, Lissner, University, Inflammation, Metformin, Death, Assistant, COVID, Research, COVID-19, Foundation, MTOR, Solution, Fluvoxamine, Health, Pharmaceutical industry, Hospital

The results were published Aug. 18 in the New England Journal of Medicine, according to Parsemus Foundation.

Key Points: 
  • The results were published Aug. 18 in the New England Journal of Medicine, according to Parsemus Foundation.
  • But you dont know whether its just coincidence until you go back to the beginning, with a rigorous randomized trial.
  • Parsemus Foundation was joined by two larger foundations also eager to see low-cost, globally-accessible medications put to the test.
  • More information on the Parsemus Foundation and the work presented here can be found at: https://www.parsemus.org/humanhealth/covid-19/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220818005438/en/

Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update

Retrieved on: 
Thursday, July 28, 2022
Pharmacology, Twitter, Telephone, Adult, Safety, MTOR, Cancer, EDT, Webcast, PDT, Aadi, FDA, Patient, LinkedIn, Nasdaq, ID, Perivascular epithelioid cell tumour, Pharmaceutical industry

LOS ANGELES, July 28, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, August 10, 2022 at 8:30 am EDT (5:30 am PDT) to report second quarter 2022 financial results and provide recent corporate updates.

Key Points: 
  • LOS ANGELES, July 28, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, August 10, 2022 at 8:30 am EDT (5:30 am PDT) to report second quarter 2022 financial results and provide recent corporate updates.
  • Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com .
  • A replay of the conference call and webcast will be archived on the website for at least 30 days.
  • More information on Aadi's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn .

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Retrieved on: 
Thursday, June 23, 2022
Doctor of Philosophy, Cancer, FDA, Risk, COVID-19, TSC2, Safety, FTSE Russell, Forward-looking statement, Index, Private Securities Litigation Reform Act, LinkedIn, ETF, Growth, CPSS-IOSCO Principles for Financial Market Infrastructures, IOSCO, Russell, Failure, GLOBE, NASDAQ, TSC1, Pharmacology, Twitter, Adult, Perivascular epithelioid cell tumour, Patient, Aadi, AADI, London Stock Exchange Group, MTOR, Pharmaceutical industry, Industrial design, Oil

The annual reconstitution of the Russell indexes captures the 4,000 largest U.S. stocks as of May 6, 2022, ranking them by total market capitalization.

Key Points: 
  • The annual reconstitution of the Russell indexes captures the 4,000 largest U.S. stocks as of May 6, 2022, ranking them by total market capitalization.
  • Membership in the U.S. all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000 Index, as well as the appropriate growth and value style indexes.
  • FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
  • For more information on the Russell indexes reconstitution, go to the Russell Reconstitution section on the FTSE Russell website .

mTOR (Mammalian Target of Rapamycin) Inhibitors Market Analysis Report 2022 by Drug Type, Indication, Route of Administration - Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 14, 2022
Health, Pharmaceutical, Kidney, Cell division, Sirolimus, US, Marketing, Blood, Market share, MTOR inhibitors, Route of administration, Food, Towa Pharmaceutical Ractab Dome, Breast cancer, Cancer, Office of Inspector General, U.S. Department of Health and Human Services, U.S. Department of Defense Strategy for Operating in Cyberspace, Pancreatic cancer, MTOR, Wilms' tumor, Everolimus, Growth, Human services, Lists of diseases, Region, Prevalence, Industry, Renal cell carcinoma, Regulation of tobacco by the U.S. Food and Drug Administration, Neoplasm, Administration, CAGR, Lymphangioleiomyomatosis, Pharmaceutical industry, Generic drug, Fine chemical, Temsirolimus

The "mTOR Inhibitors Market, by Drug Type, By Indication, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "mTOR Inhibitors Market, by Drug Type, By Indication, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Increasing product approvals from regulatory bodies is expected to drive the growth of global mTOR Inhibitors market during the forecast period.
  • Increasing number of prevalence of renal cell carcinoma is expected to drive the growth of global mTOR inhibitors market.
  • Mammalian target of rapamycin (mTOR) has common and serious class side effects of mTOR inhibitors include non-infectious pneumonitis, metabolic disorders and mucosal toxicity.